Biomarin Pharmaceutical Inc (BMRN)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$58.00

Buy

$60.00

arrow-up$1.00 (+1.72%)

Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Prices updated at 17 May 2025, 00:08 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up0.52%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Richard A. Meier
CEO
Mr. Alexander Hardy
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
3,040
Head office
770 Lindaro Street
San Rafael
United States
94901
mobile
+1 415 506-6700
letter
ir@bmrn.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Timothy P. Walbert
Independent Director
-----
Dr. Elaine J. Heron,PhD
Independent Director
0.09m--0.46m-
Mr. Richard A. Meier
Chairman of the Board
0.17m--0.72m-
Dr. Willard H. Dere, M.D.
Independent Director
0.10m--0.46m-
Mr. David E.I. Pyott, M.B.A.,M.D.
Independent Director
0.09m--0.46m-
Mr. G. Eric Davis
Executive Vice President, Chief Legal Officer and Secretary
0.72m--5.06m-
Mr. Robert J. Hombach
Independent Director
0.10m--0.47m-
Mr. Brian R. Mueller
Executive Vice President and Chief Financial Officer
0.70m--5.50m-
Dr. Athena Countouriotis, M.D.
Independent Director
0.08m--0.45m-
Mr. Mark Joseph Enyedy
Independent Director
0.10m--0.46m-
Dr. Maykin Ho, PhD
Independent Director
0.10m--0.47m-
Ms. Barbara W. Bodem
Independent Director
0.10m--0.46m-
Ms. Elizabeth McKee Anderson, M.B.A.
Independent Director
0.10m--0.46m-
Dr. Charles Greg Guyer, PhD
Chief Technical Officer and Executive Vice President
-----
Ms. Erin Burkhart
Group Vice President and Chief Accounting Officer
-----
Mr. Alexander Hardy
Director, President and Chief Executive Officer
1.05m--14.85m-
Ms. Cristin Hubbard
Executive Vice President and Chief Commercial Officer
0.38m0.60m-6.93m-
Dr. Gregory R. Friberg, M.D.
Executive Vice President and Chief Research and Development Officer
0.16m0.25m-7.22m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
BlackRock Inc23,778,9990.035312658831.13078630 Apr 202512.40
Vanguard Group Inc. ( Junked)18,992,533-18992533-30 Apr 20259.97
Vanguard Group Inc19,003,2120.02429-368973-1.90465430 Apr 20259.91
PRIMECAP Management Company17,773,2811.03868-415890-2.2864730 Apr 20259.27
Dodge & Cox14,955,2400.602552090051.41734530 Apr 20257.80

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
29 Nov 2024-Mr. Alexander Hardy66.03943,899134,156--
31 Oct 2024-Mr. Alexander Hardy56.0116,802148,451--
12 Nov 2024-Mr. Charles Greg Guyer66.37350,32468,909--
31 Oct 2024-Mr. Charles Greg Guyer56.013,08074,187--
30 Sep 2024-Mr. Gregory R. Friberg--29,060--
30 Sep 2024-Mr. Gregory R. Friberg--49,850--
30 Sep 2024-Mr. Gregory R. Friberg--21,190--
13 Sep 2024-Dr. Henry J. Fuchs,M.D.84.901,027,120185,074--
30 Apr 2024-Dr. Henry J. Fuchs,M.D.68.6520,594197,172--
13 Aug 2024-Ms. Erin Burkhart90.0064,26014,449--
28 Jun 2024-Mr. Brian R. Mueller82.3348,41071,571--
03 Jun 2024-Dr. Elaine J. Heron,PhD76.41318,47797,720--
03 Jun 2024-Dr. Elaine J. Heron,PhD-----
03 Jun 2024-Dr. Elaine J. Heron,PhD63.10318,466101,888--
03 Jun 2024-Mr. Richard A. Meier63.10416,460126,227--
03 Jun 2024-Mr. Richard A. Meier-----
03 Jun 2024-Mr. Richard A. Meier76.41416,511120,776--
30 May 2024-Mr. Brian R. Mueller63.10315,50077,159--
30 May 2024-Mr. Brian R. Mueller-----
30 May 2024-Mr. Brian R. Mueller75.19375,95072,159--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.